MedCity News July 28, 2021
Frank Vinluan

Softbank led the Series C round of funding for Deep Genomics, a startup that applies its artificial intelligence technology to all aspects of discovering and developing new drugs. The Deep Genomics platform has yielded 10 programs; CEO Brendan Frey aims to advance four of them to the clinic in two years, all while tripling the company’s pipeline.

Drug discovery and development is advancing by leaps and bounds as genetic medicines progress under a growing number of biotech companies. In the view of Brendan Frey, founder and CEO of startup Deep Genomics, while the drugs of the 20th century revolved around small molecule chemistry, drugs of the 21st century will be based on information: the sequence of letters in genetic code...

Today's Sponsors

Transcarent
SalesSparx
Canton & Company

Today's Sponsors

Oscar
Curation Health

Today's Sponsor

TripleTree

 
Topics: AI (Artificial Intelligence), Biotechnology, Investments, Pharma / Biotech, Technology, Trends
Rune Labs Lands $22.8M to for Neurology Precision Medicine Platform
Rome Therapeutics raises $77m for junk DNA-targeting drugs
Lightstone Ventures Raises $375M Fund to Invest in Early Stage Biotech and Medtech Companies
France’s biotech ecosystem is primed for growth – it’s time to feed it
MIT study finds more than 1m potential genome-editing tools in microbes